BMO Capital Markets restated their underperform rating on shares of Eli Lilly and Company (NYSE:LLY) in a report released on Wednesday morning. They currently have a $73.00 target price on the stock.

A number of other brokerages also recently weighed in on LLY. Zacks Investment Research raised shares of Eli Lilly and from a hold rating to a buy rating and set a $96.00 target price for the company in a research note on Wednesday, April 12th. Piper Jaffray Companies reaffirmed a buy rating and set a $100.00 target price on shares of Eli Lilly and in a research note on Monday, April 17th. Cowen and Company raised their target price on shares of Eli Lilly and from $85.00 to $95.00 and gave the company an outperform rating in a research note on Monday, April 17th. Morgan Stanley downgraded shares of Eli Lilly and from an overweight rating to an equal weight rating and set a $82.00 target price for the company. in a research note on Monday, April 17th. Finally, Citigroup Inc. reaffirmed a buy rating and set a $100.00 target price on shares of Eli Lilly and in a research note on Thursday, April 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of Hold and an average price target of $88.37.

Shares of Eli Lilly and (LLY) opened at 83.10 on Wednesday. The company has a market capitalization of $87.85 billion, a price-to-earnings ratio of 35.96 and a beta of 0.35. The firm’s 50-day moving average price is $82.91 and its 200-day moving average price is $81.37. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.50%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the business posted $0.86 earnings per share. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts anticipate that Eli Lilly and will post $4.15 earnings per share for the current year.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/eli-lilly-ands-nyselly-underperform-rating-reiterated-at-bmo-capital-markets/1462819.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total value of $2,069,000.00. Following the completion of the sale, the senior vice president now owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the completion of the sale, the insider now directly owns 124,265,804 shares of the company’s stock, valued at approximately $10,491,761,831.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the company. Parsec Financial Management Inc. increased its stake in Eli Lilly and by 18.9% in the second quarter. Parsec Financial Management Inc. now owns 52,705 shares of the company’s stock worth $4,338,000 after buying an additional 8,395 shares during the period. Brave Asset Management Inc. boosted its position in shares of Eli Lilly and by 45.7% in the second quarter. Brave Asset Management Inc. now owns 9,944 shares of the company’s stock valued at $818,000 after buying an additional 3,119 shares in the last quarter. Ingalls & Snyder LLC boosted its position in shares of Eli Lilly and by 1.0% in the second quarter. Ingalls & Snyder LLC now owns 18,642 shares of the company’s stock valued at $1,534,000 after buying an additional 190 shares in the last quarter. S&CO Inc. boosted its position in shares of Eli Lilly and by 17.5% in the second quarter. S&CO Inc. now owns 8,895 shares of the company’s stock valued at $732,000 after buying an additional 1,325 shares in the last quarter. Finally, River Wealth Advisors LLC boosted its position in shares of Eli Lilly and by 9.2% in the second quarter. River Wealth Advisors LLC now owns 3,305 shares of the company’s stock valued at $272,000 after buying an additional 279 shares in the last quarter. 75.56% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.